T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies
Summary:
The National Cancer Institute (NCI) seeks licensees for this invention comprising (1) a novel T cell receptor (TCR) specific to the E2 protein of Human papillomavirus (HPV) type 6 in the context of the human leukocyte antigen, HLA-B55, and (2) a panel of Cos7 cells expressing different HLA proteins for validation of T cell responses in immunotherapies for low-risk HPV-related diseases such as recurrent respiratory papillomatosis and anogenital condyloma.
Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy
Summary:
The National Cancer Institute (NCI) is seeking research co-development partners and/or licensees for NCI’s compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines.
Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1
Summary:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is actively seeking potential licensees interested in further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of cancer, infectious diseases, and autoimmune diseases.
Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a set of Chimeric Antigen Receptors (CARs) that target the γδ T-Cell Receptor.
Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy
Summary:
The National Cancer Institute (NCI) seeks capable licensees interested in commercializing T cell receptor (TCR)-engineered T cells expressing murine/human hybrid receptors.
Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s)
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for development of papilloma-infiltrating lymphocytes (PIL) as treatment for patients with chronic human papillomavirus (HPV) 6 or 11 infections.
Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21
3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases
Summary:
Lung metastases represent a major clinical challenge in advanced cancer, with poor survival rates and no effective therapies to prevent their development. Researchers at the National Cancer Institute (NCI) have developed C24:2, a first-in-class synthetic 3-O-sulfo-galactosylceramide analog. After lysosomal processing by dendritic cells, C24:2 switches immune specificity to activate type I NKT cells, triggering a potent IFN-γ–mediated Th1 response.
Devices for Improved Tissue Cryopreservation and Recovery
Problem: Cryopreservation is a process where living biological materials like cells, tissues, and cell therapies (which are susceptible to damage caused by unregulated chemical kinetics) are preserved by cooling to very low temperatures in the presence of specific cryopreservation media that protects the biological material from damage. In order to be used, the biological material ideally should be thawed in a controlled manner that minimizes damage and desirably brings the material back to a viable state.